🌐 Also available in: 🇩🇪 Deutsch
Original source: World Medical Innovation Forum
This video from World Medical Innovation Forum covered a lot of ground. Streamed.News selected 8 key moments and summarises them here. Everything below links directly to the timestamp in the original video.
As new complex treatments for heart conditions emerge, understanding how they should be combined and for whom becomes critical, balancing medical efficacy with affordability.
Clinical Trials Crucial for ATTR-CM Combination Therapies
Experts anticipate that future combination therapies for ATTR-CM, including emerging monoclonal antibody-based clearance medicines, will require rigorous clinical trials to determine optimal patient selection. Given the high cost of current ATTR-CM treatments, these trials are essential to identify which patients will benefit most from single versus multiple medications, ensuring cost-effectiveness.
Panelists emphasized that not all patients will likely need every available medicine. Earlier diagnosis, potentially aided by AI-powered ECG tools, will be critical for stratifying patients and understanding the appropriate timing for these advanced therapies, especially as the patient population expands.
"My suspicion is that not every single patient is going to need every single medicine but we would need the trials to help us identify who would need one or multiple."
LP(a) Lowering Drugs Show Promise for Cardiovascular Disease
Panelists express high confidence in emerging drugs designed to lower lipoprotein(a) (LP(a)), a causal biomarker for cardiovascular disease risk. Based on robust human genetic studies and favorable side effect profiles observed in early trials, experts anticipate positive results from upcoming clinical trials, despite some theoretical concerns about the precise mechanisms.
While the industry is investing heavily in these new medicines, careful patient selection will be crucial for maximizing their benefit, especially for individuals with the highest LP(a) levels. The nuanced approach to identifying target populations will determine the long-term success and adoption of these therapies.
"The current trials suggest that they're pretty favorable as far as side effect profiles. That's one way that obviously it could be thrown off. A key aspect will be patient selection."
ATTR-CM Significantly Underdiagnosed, Imaging Drives Early Detection
ATTR-CM (transthyretin amyloid cardiomyopathy) remains substantially underdiagnosed globally, despite being a significant contributor to heart failure. The introduction of specific therapies, such as tafamidis, has spurred increased efforts to identify patients earlier, with advanced imaging techniques becoming the primary driver of improved diagnosis rates.
While current therapies show real benefit, challenges persist with treatment access due to cost and patient funneling into therapeutic pathways. Early diagnosis is crucial, as experimental data suggest that interventions are most impactful when administered in the disease's initial stages, paving the way for future emerging agents.
"I think the biggest impact… is once you have some form of therapy you do strive much harder to identify the subsets."
GLP-1 Agonists Offer Cardiovascular Benefit Beyond Weight Loss
The exact mechanism by which GLP-1 receptor agonists like semaglutide and tirzepatide reduce cardiovascular events, beyond weight loss and A1C reduction, remains largely unknown. Panelists highlighted that these drugs improve multiple cardiometabolic parameters, suggesting a multifactorial benefit rather than a single pathway.
Evidence of weight-independent effects includes albuglide, an older GLP-1 agonist that reduced cardiovascular outcomes in diabetic patients without inducing weight loss. This indicates that direct anti-inflammatory properties or other pleiotropic effects likely contribute to their observed cardiovascular benefits.
"For me, that's the strongest evidence that suggests that there may be other weight-independent effects."
Oral PCSK9 Inhibitors Poised for Market Niche
Panelists predict a significant market niche for new oral PCSK9 inhibitors, despite the existing convenience of twice-yearly injectable options like inclisiran. The slow uptake of current injectable PCSK9 therapies indicates a large unmet need among patients, which an oral medication could effectively address.
While patients are becoming more accustomed to injectable drugs, the availability of an oral PCSK9 inhibitor is expected to see brisk adoption, particularly among those who prefer non-injectable forms. This could reshape the competitive landscape for lipid-lowering treatments, even if injectables maintain their place for some patients.
"Uptakes's obviously been slow and so there's clearly a a need. There's a place to be filled and it seems that noral medication could easily do that."
New Aldosterone Synthase Inhibitors May Replace Spironolactone in Men
New aldosterone synthase inhibitors are expected to significantly impact the treatment of hypertension, particularly for male patients currently prescribed spironolactone. Panelists noted that approximately 50% of male patients experience gynecomastia or similar symptoms with spironolactone, a side effect supported by clinical data.
The availability of an alternative with a more favorable side effect profile could lead to rapid adoption among men who have responded to mineralocorticoid axis manipulation. While the situation for women may be more complex, the new class of drugs offers the potential for improved patient tolerance and adherence, particularly if hypertension is carefully stratified.
"In my experience about 50% of all male patients complain about gynecomastia. And so if there was an alternative that you could replace..."
Aldosterone Synthase Inhibitors Offer Promise for Hypertension but Not a 'Silver Bullet'
Hypertension remains the most common global risk factor, often complicated by medication side effects and adherence challenges. Panelists noted that while new aldosterone synthase inhibitors offer a favorable side effect profile and reasonable potency, achieving approximately 9-10 mmHg systolic blood pressure lowering, they are not a complete solution.
The complexity of hypertension means that simply adding another pill will not automatically resolve the issue. Patient adherence and overcoming various barriers to medication uptake remain crucial challenges that these new drugs, despite their benefits, may not fully address.
"Hypertension is very complicated. Just adding another pill is may not immediately solve the solution of hypertension."
LP(a) Lowering Drugs Need Significant Risk Reduction for Adoption
For new lipoprotein(a) (LP(a)) lowering drugs to achieve clinical significance and widespread adoption, they will likely need to demonstrate at least a 15-20% reduction in cardiovascular events in high-risk patients. Panelists emphasized that this threshold is necessary given the existence of multiple other disease-modifying therapies and a competitive market.
To achieve such an effect size, careful patient selection targeting individuals with the highest LP(a) levels and residual risk will be crucial. While genetic studies offer insights, the ultimate validation will come from clinical trials demonstrating potent lowering and meaningful outcomes, especially if the drug is to command additional payment on top of existing treatments.
"I think you're going to need to see 20% plus effects for anybody to really notice especially for anybody to pay additionally on top of existing therapies..."
Summarised from World Medical Innovation Forum · 39:31. All credit belongs to the original creators. World Medical Innovatio Forum summarises publicly available video content.
